Scott L Pomeroy

List of Publications by Year in Descending Order

66 papers	36,126 citations	40 h-index	92 g-index
92 ext. papers	47,236 ext. citations	15.2 avg, IF	6.26 L-index

#	Paper	IF	Citations
66	Validation of a computational phenotype for finding patients eligible for genetic testing for pathogenic PTEN variants across three centers.. *Journal of Neurodevelopmental Disorders*, **2022**, 14, 24	4.6	0
65	SEQing to find hidden medulloblastoma cells. *Cancer Cell*, **2021**, 39, 1452-1454	24.3	
64	TORC1/2 kinase inhibition depletes glutathione and synergizes with carboplatin to suppress the growth of MYC-driven medulloblastoma. *Cancer Letters*, **2021**, 504, 137-145	9.9	1
63	Children\'s Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma. *Journal of Clinical Oncology*, **2021**, 39, 2685-2697	2.2	12
62	Loss of Consciousness in the Young Child. *Pediatric Cardiology*, **2021**, 42, 234-254	2.1	2
61	Epigenetics and survivorship in pediatric brain tumor patients. *Journal of Neuro-Oncology*, **2020**, 150, 77-83	4.8	3
60	Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. *Acta Neuropathologica*, **2020**, 139, 223-241	14.3	28
59	Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and Relapse. *Cancer Cell*, **2019**, 36, 302-318.e7	24.3	49
58	Intellectual and developmental disabilities research centers: Fifty years of scientific accomplishments. *Annals of Neurology*, **2019**, 86, 332-343	9.4	1
57	Resolving medulloblastoma cellular architecture by single-cell genomics. *Nature*, **2019**, 572, 74-79	50.4	133
56	Medulloblastoma. *Nature Reviews Disease Primers*, **2019**, 5, 11	51.1	202
55	PDTM-24. PINEOBLASTOMA SEGREGATES INTO MOLECULAR SUBTYPES WITH DISTINCT CLINICOPATHOLOGIC FEATURES: REPORT FROM THE RARE BRAIN TUMOUR CONSORTIUM. *Neuro-Oncology*, **2019**, 21, vi192-vi192	1	78
54	PDTM-32. RESOLVING MEDULLOBLASTOMA CELLULAR ARCHITECTURE BY SINGLE-CELL GENOMICS. *Neuro-Oncology*, **2019**, 21, vi194-vi194	1	78
53	Brain cancer genomics and epigenomics. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2018**, 148, 785-797	3	4
52	Rapid discrimination of pediatric brain tumors by mass spectrometry imaging. *Journal of Neuro-Oncology*, **2018**, 140, 269-279	4.8	29
51	Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups. *Cancer Cell*, **2018**, 34, 396-410.e8	24.3	74
50	EMBR-17. PINEOBLASTOMA SEGREGATES INTO MOLECULAR SUBTYPES WITH DISTINCT CLINICOPATHOLOGIC FEATURES: REPORT FROM THE RARE BRAIN TUMOR CONSORTIUM. *Neuro-Oncology*, **2018**, 20, i72-i73	1	78

49	MicroRNA-1301 suppresses tumor cell migration and invasion by targeting the p53/UBE4B pathway in multiple human cancer cells. *Cancer Letters*, **2017**, 401, 20-32	9.9	28
48	Medulloblastoma: Molecular Classification-Based Personal Therapeutics. *Neurotherapeutics*, **2017**, 14, 265-273	6.4	47
47	SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation. *Nature Genetics*, **2017**, 49, 289-295	36.3	172
46	The evolution of medulloblastoma therapy to personalized medicine. *F1000Research*, **2017**, 6, 490	3.6	21
45	The whole-genome landscape of medulloblastoma subtypes. *Nature*, **2017**, 547, 311-317	50.4	472
44	MB-103DiSCoVERing INNOVATIVE THERAPIES: COMBINING GENETICALLY ACCURATE DISEASE MODELS OF MEDULLOBLASTOMA WITH ADVANCED IN SILICO ANALYSIS TO IDENTIFY NOVEL THERAPEUTIC TARGETS. *Neuro-Oncology*, **2016**, 18, iii120.3-iii120	1	78
43	Tracking the Fate of Cells in Health and Disease. *New England Journal of Medicine*, **2016**, 375, 2494-2496	59.2	1
42	Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. *Acta Neuropathologica*, **2016**, 131, 821-31	14.3	324
41	DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets. *Clinical Cancer Research*, **2016**, 22, 3903-14	12.9	43
40	Defining the molecular landscape of ependymomas. *Cancer Cell*, **2015**, 27, 613-5	24.3	25
39	Incidence, risk factors, and longitudinal outcome of seizures in long-term survivors of pediatric brain tumors. *Epilepsia*, **2015**, 56, 1599-604	6.4	40
38	MB-27 * PATHWAY ANALYSIS OF A HUMAN NEURAL STEM CELL MODEL OF AGGRESSIVE MEDULLOBLASTOMA REVEALS CKD INBHIBITION AS A POTENTIAL THERAPEUTIC MODALITY. *Neuro-Oncology*, **2015**, 17, iii25-iii26	1	78
37	Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. *Cancer Cell*, **2014**, 25, 393-405	24.3	469
36	The G protein □subunit G□ is a tumor suppressor in Sonic hedgehog-driven medulloblastoma. *Nature Medicine*, **2014**, 20, 1035-42	50.5	82
35	Cytogenetic prognostication within medulloblastoma subgroups. *Journal of Clinical Oncology*, **2014**, 32, 886-96	2.2	199
34	WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. *Acta Neuropathologica Communications*, **2014**, 2, 174	7.3	32
33	Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. *Nature Genetics*, **2013**, 45, 927-32	36.3	550
32	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. *Lancet Oncology, The*, **2013**, 14, 1200-7	21.7	226

31	Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. *Journal of Clinical Oncology*, **2013**, 31, 2927-35	2.2	290
30	Medulloblastomics: the end of the beginning. *Nature Reviews Cancer*, **2012**, 12, 818-34	31.3	443
29	Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. *Acta Neuropathologica*, **2012**, 123, 615-26	14.3	265
28	Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. *Nature*, **2012**, 488, 106-10	50.4	552
27	Medulloblastoma biology in the post-genomic era. *Future Oncology*, **2012**, 8, 1597-604	3.6	6
26	Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma. *Acta Neuropathologica*, **2012**, 123, 539-52	14.3	132
25	Dissecting the genomic complexity underlying medulloblastoma. *Nature*, **2012**, 488, 100-5	50.4	623
24	Molecular subgroups of medulloblastoma: the current consensus. *Acta Neuropathologica*, **2012**, 123, 465-72	14.3	1167
23	Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. *Acta Neuropathologica*, **2012**, 123, 473-84	14.3	678
22	Hedgehog-GLI pathway in medulloblastoma. *Journal of Clinical Oncology*, **2012**, 30, 2154-6	2.2	27
21	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. *Nature*, **2012**, 488, 49-56	50.4	596
20	Neuro-oncology training for the child neurology resident. *Seminars in Pediatric Neurology*, **2011**, 18, 120-2	2.9	
19	Posterior fossa ependymomas: a tale of two subtypes. *Cancer Cell*, **2011**, 20, 133-4	24.3	14
18	Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. *Journal of Clinical Oncology*, **2011**, 29, 1424-30	2.2	513
17	Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features. *Journal of Clinical Oncology*, **2011**, 29, 1415-23	2.2	58
16	Neuralized1 causes apoptosis and downregulates Notch target genes in medulloblastoma. *Neuro-Oncology*, **2010**, 12, 1244-56	1	27
15	Molecular genetics of pediatric central nervous system tumors. *Current Oncology Reports*, **2006**, 8, 423-9	6.3	13
14	Microarray Analysis and Proteomic Approaches to Drug Development **2006**, 74-88		1

List of Publications

13	Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 15545-50	11.5	24578
12	Conserved mechanisms across development and tumorigenesis revealed by a mouse development perspective of human cancers. *Genes and Development*, **2004**, 18, 629-40	12.6	129
11	Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. *Journal of Clinical Oncology*, **2004**, 22, 994-8	2.2	70
10	Neural development and the ontogeny of central nervous system tumors. *Neuron Glia Biology*, **2004** , 1, 127-33		3
9	Medulloblastoma tumorigenesis diverges from cerebellar granule cell differentiation in patched heterozygous mice. *Developmental Biology*, **2003**, 263, 50-66	3.1	77
8	Molecular biology of medulloblastoma therapy. *Pediatric Neurosurgery*, **2003**, 39, 299-304	0.9	23
7	Prediction of central nervous system embryonal tumour outcome based on gene expression. *Nature*, **2002**, 415, 436-42	50.4	1857
6	Focus on central nervous system neoplasia. *Cancer Cell*, **2002**, 1, 125-8	24.3	115
5	Circulating serpin tumor markers SCCA1 and SCCA2 are not actively secreted but reside in the cytosol of squamous carcinoma cells. *International Journal of Cancer*, **2000**, 89, 368-77	7.5	60
4	Identification of PATCHED mutations in medulloblastomas by direct sequencing. *Human Mutation*, **2000**, 16, 89-90	4.7	47
3	Neurotrophins in cerebellar granule cell development and medulloblastoma. *Journal of Neuro-Oncology*, **1997**, 35, 347-52	4.8	22
2	Postnatal addition of satellite cells to parasympathetic neurons. *Journal of Comparative Neurology*, **1996**, 375, 518-25	3.4	8
1	Magnetic resonance imaging changes after stereotactic radiation therapy for childhood low grade astrocytoma. *Cancer*, **1996**, 78, 864-73	6.4	47